Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 4 1Phase 2 1

Status

Terminated 1Completed 1

Sponsor Class

OTHER 10INDUSTRY 2NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Classical hematology 2Gastrointestinal 1

Conditions

Venous Thrombosis 2Venous Thromboembolism 2Pulmonary Embolism 2Neoplasms 1Gastrointestinal Neoplasms 1

Interventions

Carboplatin 315Paclitaxel 303Cisplatin 250Docetaxel 238pembrolizumab 230Gemcitabine 214Pemetrexed 158Capecitabine 147Rituximab 144Bevacizumab 142Dexamethasone 125Fluorouracil 121Cyclophosphamide 102Trastuzumab 100Doxorubicin 96Nivolumab 93Prednisone 92Oxaliplatin 90atezolizumab 75Leucovorin 72durvalumab 69130-nm albumin-bound paclitaxel 68Injections 66Lenalidomide 63Irinotecan 62Bortezomib 56Letrozole 54Topotecan 53Fulvestrant 53Drug Therapy 50

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × INDUSTRY × Dalteparin × Clear all
NCT05171075 2026-04-17

MAGNOLIA

Anthos Therapeutics, Inc.

Phase 3 Terminated
417 enrolled
Classical hematologyGastrointestinal

Gastrointestinal Neoplasms, Pulmonary Embolism, Venous Thrombosis, Venous Thromboembolism

NCT02073682 2019-03-06

Cancer Venous Thromboembolism (VTE)

Daiichi Sankyo

Phase 3 Completed
1,046 enrolled 24 charts
Classical hematology

Neoplasms, Pulmonary Embolism, Venous Thrombosis, Venous Thromboembolism

Data powered by HemOnc (CC BY 4.0) Colophon âš¡